Role of extracellular glutamate measured by cerebral microdialysis in severe traumatic brain injury

Clinical article

ROUKOZ CHAMOUN, M.D.,1 DIMA SUKI, PH.D.,2 SHANKAR P. GOPINATH, M.D.,1 J. CLAY GOODMAN, M.D.,3 AND CLAUDIA ROBERTSON, M.D.1

Departments of 1Neurosurgery and 3Pathology, Baylor College of Medicine; and 2Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Object. Authors of several studies have implied a key role of glutamate, an excitatory amino acid, in the pathophysiology of traumatic brain injury (TBI). However, the place of glutamate measurement in clinical practice and its impact on the management of TBI has yet to be elucidated. The authors’ objective in the present study was to evaluate glutamate levels in TBI, analyzing the factors affecting them and determining their prognostic value.

Methods. A prospective study of patients with severe TBI was conducted with an inclusion criterion of a Glasgow Coma Scale score ≤ 8 within 48 hours of injury. Invasive monitoring included intracranial pressure measurements, brain tissue PO₂, jugular venous O₂ saturation, and cerebral microdialysis. Patients received standard care including mass evacuation when indicated and treatment of elevated intracranial pressure values. Demographic data, CT findings, and outcome at 6 months of follow-up were recorded.

Results. One hundred sixty-five patients were included in the study. Initially high glutamate values were predictive of a poor outcome. The mortality rate was 30.3% among patients with glutamate levels > 20 µmol/L, compared with 18% among those with levels ≤ 20 µmol/L.

Two general patterns were recognized: Pattern 1, glutamate levels tended to normalize over the monitoring period (120 hours); and Pattern 2, glutamate levels tended to increase with time or remain abnormally elevated. Patients showing Pattern 1 had a lower mortality rate (17.1 vs 39.6%) and a better 6-month functional outcome among survivors (41.2 vs 20.7%).

Conclusions. Glutamate levels measured by microdialysis appear to have an important role in TBI. Data in this study suggest that glutamate levels are correlated with the mortality rate and 6-month functional outcome.

(DOI: 10.3171/2009.12.JNS09689)

KEY WORDS • severe head injury • microdialysis • glutamate • outcome

GLUTAMATE is the predominant excitatory neurotransmitter in the mammalian CNS and is essentially present in the intracellular space. Normally, extracellular glutamate is thought to be retrieved via plasma membrane transporters. However, when present in large amounts in the extracellular compartment, glutamate can be toxic to neurons. The significant increase in the extracellular concentration of glutamate in the case of CNS injury or disease has been linked to a number of potential mechanisms including excessive release and impaired cellular uptake. “Excitotoxicity” is the term used to describe the neurotoxicity induced by glutamate or glutamate receptor agonists. The overactivation of glutamate receptors has been shown to induce an excessive influx of Na⁺ and Ca²⁺, mitochondrial dysfunction, and dendritic morphological changes ultimately leading to cell death by either rapid necrosis or delayed apoptosis.

In recent years, there has been increased interest in the role of glutamate in neurotrauma. Animal as well as a small number of human studies utilizing microdialysis have documented a marked elevation in the extracellular fluid level of glutamate in TBI. Despite the potential role of elevated extracellular glutamate levels in the pathophysiology of severe TBI and its proposed impact on the

Abbreviations used in this manuscript: GCS = Glasgow Coma Scale; GOS = Glasgow Outcome Scale; ISS = Injury Severity Score; MABP = mean arterial blood pressure; NMDA = N-methyl-D-aspartic acid; SvO₂ = jugular venous oxygen saturation; TBI = traumatic brain injury.

This article contains some figures that are displayed in color online but in black and white in the print edition.
Role of glutamate in severe traumatic brain injury

Patient outcome, however, cerebral microdialysis seems far from being incorporated into routine clinical practice at this point. Numerous questions remain unanswered, and this field continues to be an active area of research. The need for a better understanding of the molecular events in TBI, potentially leading to a more effective targeted therapy, will undoubtedly continue to fuel similar studies in the future.

In this paper, we report the results of a prospective study in which cerebral microdialysis was used in severe blunt TBI. Objectives of the study were as follows: 1) to determine the incidence of patients showing an early elevation in glutamate levels; 2) to study the changes in glutamate levels over the monitoring period (120 hours); and 3) to determine the prognostic value of extracellular glutamate (early values and trends of glutamate levels).

Methods

Study Design

This prospective study was conducted at the Ben Taub General Hospital (a Level I trauma center) in Houston, Texas, between April 2000 and February 2007. Inclusion criteria were as follows: TBI, a blunt mechanism of head trauma, and a GCS score ≤ 8 on presentation or within 48 hours of injury. Exclusion criteria included a penetrating head injury, a presentation GCS score of 3, and fixed, dilated pupils. The Baylor Institutional Review Board approved the research protocol, and informed consent to participate in the study was obtained from each patient's nearest relative. Overall, 165 patients were included in the study.

Patient Care

Patients were treated in the neurointensive care unit following a standard protocol. All patients underwent CT scanning of the brain on presentation in the emergency room. Patients with a surgically treatable mass (subdural hematoma, epidural hematoma, or large contusion with mass effect) were immediately taken to the operating room. All patients underwent insertion of an ICP monitor using a ventriculostomy catheter (in a small number of patients, an intraparenchymal ICP monitor was inserted instead because of collapsed ventricles), a brain tissue PO2 monitor, and an SjvO2 monitor either in the intensive care unit or intraoperatively in the case of a surgically treatable lesion. All patients were intubated and sedated. The head of the bed was kept elevated at 30°. Patients were kept euvoletic and isothermic, and enteral feeding was started 24 hours after admission. Hypotensive episodes were treated using fluid replacement and vasopressors. Intracranial pressure levels > 20 mm Hg were treated with ventricular drainage of CSF, mannitol, and mild hyperventilation (Paco2: 30–35 mm Hg). If treatment of the increased ICP was not successful, barbiturate coma with burst suppression was induced. Decompressive craniectomy was then indicated for the management of intractable high ICP if all other measures failed.

Monitoring SjvO2 and Brain Tissue PO2

Jugular venous O2 saturation was measured using a fiberoptic catheter placed in the dominant internal jugular vein and positioned so that the catheter tip was in the jugular bulb, as verified by a lateral skull radiograph. The dominant internal jugular vein was determined by comparing the ICP increase caused by compression of each internal jugular vein and/or by using Doppler ultrasonography. The catheter was calibrated at the time of insertion and every 8–12 hours thereafter.

Brain tissue PO2 was measured using a miniaturized Clark electrode (Licox catheter, GMS) that was inserted at the same time of ventriculostomy insertion. The probe was positioned in the cortex, tunneled subgaleally, and secured. An area of brain in the frontotemporal region that appeared injured but not clearly necrotic was targeted for probe placement. Calibration of the probe was performed according to the manufacturer's specifications. Oxygen tension in addition to other parameters was used to determine patient care. When brain tissue PO2 values < 10 mm Hg are recorded, treatable causes of global tissue hypoxia—for example, hypotension, high ICP, hypoxemia, or anemia—are looked for first and treated. If no evidence of global tissue hypoxia is present, then a regional cause is suspected, such as an evolving contusion near the probe.

Microdialysis Technique

Microdialysis probes (molecular weight cutoff of 20 kDa, 10-mm membrane, CMA-70, CMA Microdialysis) were placed in the brain parenchyma in the same general area of the brain as the brain tissue PO2 probe. The probes were perfused with CNS perfusion fluid at 3 µl/minute (P000151, CMA Microdialysis), and samples were collected every hour. Concentrations of glutamate in the microdialysate were analyzed using the CMA-600 microdialysis analyzer.

Data Collection

Patient demographics (age, sex, and race), mechanism of injury, neurological examination results, GCS score, ISS, and CT findings were all noted. Mean arterial blood pressure, ICP, brain tissue PO2, and SjvO2 were recorded every hour. Patient outcome was determined at 6 months of follow-up. Survival rate and functional outcome based on the GOS were recorded. A neuropsychology technician collected the 6-month follow-up data through direct interviews with patients in the clinic and occasionally by phone calls when the direct interview was not possible.

Analyses of glutamate data were done using values measured during the first 120 hours. After 120 hours the microdialysis catheter was usually removed, and patients continued to be treated according to our standard protocol. The correlation between glutamate values and the severity of injury, outcome, or other monitored parameters was analyzed.

Statistical Analysis

The chi-square test and Wilcoxon rank-sum test were used to assess bivariate associations. Pearson and Spearman correlation coefficients were obtained for correlations between the hourly values of glutamate levels and other (hourly) recorded parameters such as MABP, ICP, brain tis-
sue PO₂, or SjvO₂. The logistic regression model was used to determine factors associated with survival at 6 months. Univariate and multivariate odds ratios and their 95% confidence intervals were obtained. All tests were 2-tailed. A p value < 0.05 was considered significant. The software package SPSS 16.0 (SPSS, Inc.) was used for the statistical analyses.

**Results**

**Clinical Characteristics and Patient Outcomes**

One hundred sixty-five consecutive patients met the inclusion criteria and were included in this study. All patients with a GCS score ≤ 8 within 48 hours of injury underwent invasive monitoring of ICP, brain tissue PO₂, and SjvO₂, and a microdialysis catheter was inserted. Invasive monitoring devices were removed when ICP was well controlled (without requiring mannitol, CSF drainage, or heavy sedation) and/or the patient showed significant improvement in neurological status. Clinical and radiological characteristics are summarized in Tables 1 and 2. At 6 months of follow-up, the mortality rate was 23.6%. Among those who survived, 46 patients had a good functional outcome (GOS Score 4 or 5). Patient outcomes at 6 months of follow-up are summarized in Table 3.

**Early Glutamate Levels**

The average values of glutamate in the microdialysate in the first 24 hours of monitoring were < 10 µmol/L in 31 patients (18.8%), between 10 and 20 µmol/L in 58 patients (35.1%), and > 20 µmol/L in 76 patients (46.1%). There was a clear trend of a higher mortality rate among patients with an average glutamate level > 20 µmol/L (30% compared with 18% for ≤ 20 µmol/L); however, this difference did not reach statistical significance (p = 0.08). No correlation was found between early glutamate levels and age, CT findings, or ISS. As stated in Methods, the microdialysis probes were inserted in an area of the brain that appeared to be injured but not clearly necrotic; thus, normal brain areas and frank contusions were both avoided. As a result, there was minimal variation in the location of the probes in general, probably accounting for the lack of correlation between the measured glutamate levels and CT findings such as the Marshall categories. There was also no correlation between early glutamate levels and GCS scores on presentation or initial ICP. While clinical examination (GCS score), ICP, and molecular markers (glutamate, for example) all in some way reflect the severity of a brain injury, they do not necessarily measure the same thing. They all are independent prognostic factors, but they do not necessarily exactly correlate with each other in all patients.

**Changes in Glutamate Levels During the 120-Hour Monitoring Period**

Two main general patterns were identified regarding changes in the glutamate levels over time (Fig. 1). In Pattern 1, glutamate levels tended to normalize over the monitoring period. Two trends could be identified as subgroups of this pattern: first, the levels were initially low and remained low; and second, levels were initially high but decreased over time. In Pattern 2, glutamate levels tended to increase over time or remain abnormally elevated. Three trends were identified as subgroups of this pattern: first, levels were initially low but increased over time; second, levels were initially high and remained ab-
Role of glutamate in severe traumatic brain injury

Normally high; and third, levels were initially high and continued to increase.

These patterns and trends correlated with the mortality rates. The mortality rate was 17.1% for Pattern 1 compared with 39.6% for Pattern 2 (Table 4). This difference was statistically significant on univariate (p = 0.02) and multivariate analyses (p = 0.02). Overall, 4 different factors were associated with higher mortality rates in this study: glutamate patterns, GCS score on presentation, age, and CT Marshall categories (Table 5). Of note, patients who initially presented with a high GCS score and whose condition then deteriorated within 48 hours to a score ≤ 8 were treated similarly to those presenting with a low GCS score. Overall, these patients had a better outcome as predicted by their higher GCS score on presentation.

Patterns of changes in glutamate levels were also found to have a correlation with functional outcome among survivors. Among patients showing Pattern 1, 41.2% of those who survived had a good functional outcome at 6 months of follow-up (GOS Score 4 or 5), compared with 20.7% among patients showing Pattern 2. The differences were statistically significant on both univariate (p = 0.05) and multivariate analyses (p = 0.03).

Impact of Ischemia, Hypotension, and Increased ICP on Glutamate Levels

When analyzing the entire series of patients, no statistically significant correlation was found between the hourly glutamate levels and other (hourly) recorded parameters such as MABP, ICP, brain tissue PO₂, or SjvO₂—meaning that transient changes in ICP or O₂ tension were unlikely to affect glutamate levels. In most cases, however, we observed a general trend of correlation. A significant rise in glutamate levels was usually seen during episodes of sustained increase in ICP or poor brain perfusion and/or oxygenation. Illustrative examples of such correlations are shown in Figs. 2 and 3.

Discussion

The release of neurochemical messengers is an inte-
gral part of cellular signaling; however, excessive release of these agents can contribute to CNS injuries. Microdialysis involves the sampling of substances dissolved in the extracellular fluid by perfusing a fluid across a semi-permeable membrane in a probe inserted into the area of interest in the brain. This technique has been used to foster a better understanding of secondary TBI damage caused by the excessive release of neurotransmitters. The potential clinical implication of such knowledge can be crucial given that the treatment of TBI during neurointensive care is aimed at preventing or minimizing the burden of secondary injury.

Glutamate in Animal and Clinical Studies

The interest in glutamate measurement through microdialysis in human TBI has been fueled by promising findings in animal studies. Experiments in rats have shown that TBI results in a severity-dependant release of glutamate and that NMDA receptor antagonists can improve TBI outcome in rats. Bullock et al. have used intracerebral microdialysis to study excitatory amino acid release in severe TBI in 80 consecutive human patients. Their main findings were as follows: 1) Dialysate excitatory amino acids were elevated in 30% of their patient population. 2) In contradistinction to animal studies showing a transient and brief increase in glutamate after TBI, the elevated levels in human TBI can persist up to 4 days. 3) High glutamate levels are correlated with high ICP and poor outcome.

Main Study Findings

Early elevated levels of glutamate (averaging > 20 µmol/L in the first 24 hours) were seen in 46.1% of patients in this series. Although the mortality rate at 6 months of follow-up was higher among patients who had shown initially elevated levels (30% mortality rate for levels > 20 µmol/L vs 18% for levels ≤ 20 µmol/L), this difference did not reach statistical significance (p = 0.08).

Glutamate level changes over 120 hours of monitoring followed 1 of 2 general patterns that could be subdivided into several trends. These patterns and trends were highly correlated with the mortality rate and functional outcome at 6 months of follow-up.

When glutamate levels tended to normalize over time (observed in 71% of patients in this series), the mortality rate was 17.1%; and 41.2% of those who survived ultimately achieved a good functional outcome. When the levels tended to increase over time or remained abnormally elevated (observed in 29% of patients in this series), the mortality rate was 39.6%; and 20.7% of those who survived had a good functional outcome.

The hourly glutamate levels did not seem to be affected by transient hemodynamic or ICP changes because there was no correlation between glutamate and other hourly measured parameters such as MABP, ICP, brain tissue PO2, or SjvO2. However, a persistent elevation in ICP or persistent poor brain tissue oxygenation was closely related to an increase in glutamate levels.

Potential Impact on Therapy

It has been proposed that supraphysiological levels of excitatory amino acids (primarily glutamate) overstimulate the NMDA receptors leading to Na+ and Ca2+ influx and K+ efflux and ultimately resulting in neuronal death and brain swelling. Several categories of excitatory amino acid inhibitors exist: pre- and postsynaptic blockers, which inhibit the activation of different recep-

<table>
<thead>
<tr>
<th>Comparison</th>
<th>p Value on Univariate Analysis</th>
<th>p Value on Multivariate Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pattern 2 vs Pattern 1</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>presentation GCS score &lt;7 vs ≥7</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>median age &gt;34 yrs vs &lt;34 yrs</td>
<td>0.03</td>
<td>0.04</td>
</tr>
<tr>
<td>CT Marshall code M vs D</td>
<td>&lt;0.01</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Note that previous studies have suggested that the normal glutamate level is 16 ± 16 µmol/L.
Role of glutamate in severe traumatic brain injury

In accordance with the rest of the literature, data in this study show that glutamate plays an important role in TBI. High glutamate levels are present in a substantial number of patients, and patterns of glutamate level changes are predictive of patient outcome. Although previously reported studies using a number of excitatory amino acid inhibitors have failed to show an improvement in outcome, further research in this area is warranted. The main directions for future trials would be identifying a subgroup of patients that may benefit from this form of therapy and minimizing the side effects of the drugs used. The present study showed that glutamate levels measured by microdialysis have a prognostic value. However, whether these levels can be used to direct disease management and ultimately improve patient outcomes must be evaluated in future studies.

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

This study was supported by National Institutes of Health Grant No. P01-NS38660.

Author contributions to the study and manuscript preparation include the following. Conception and design: SP Gopinath, C Robertson. Acquisition of data: SP Gopinath, C Robertson. Analysis and interpretation of data: RB Chamoun. Drafting the article: RB Chamoun. Critically revising the article: JC Goodman, C Robertson. Reviewed final version of the manuscript and approved it for submission: SP Gopinath, RB Chamoun, D Suki, JC Goodman, C Robertson. Statistical analysis: D Suki. Administrative/technical/material support: JC Goodman. Study supervision: C Robertson.
References


Manuscript submitted April 27, 2009. Accepted December 16, 2009. Please include this information when citing this paper: published online January 29, 2010; DOI: 10.3171/2009.12.JNS09689. Address correspondence to: Shankar P. Gopinath, M.D., Department of Neurosurgery, Baylor College of Medicine, 1709 Dryden, Suite 750, Houston, Texas 77030. email: shankarg@bcm.tmc.edu.